Ramon L Ramirez1, Vinicio De Jesus Perez2,3, Roham T Zamanian2,3. 1. Department of Medicine. 2. Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine. 3. Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford, California.
Abstract
PURPOSE OF REVIEW: Methamphetamine is a highly addictive drug originally developed for the treatment of neuropsychiatric disorders. At present, the epidemic rise of illicit methamphetamine use has increased the number of patients living with medical complications. Our group has recently identified a definite association between methamphetamine use and pulmonary arterial hypertension (PAH), a life-threatening disease characterized by occlusive vasculopathy and progressive right heart failure. This review will discuss the evidence that links methamphetamine with PAH and how to approach the diagnosis and management of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) patients in clinic. RECENT FINDINGS: Compared with idiopathic (I) PAH, Meth-APAH patients present with worse functional status, right ventricular dysfunction, and exercise tolerance. Despite therapy, the 5-year survival of Meth-APAH patients is significantly lower compared with IPAH. Genetic studies suggest that loss of function variants in genes involved in drug detoxification can increase susceptibility for methamphetamine-related vascular injury and trigger occlusive vasculopathy. SUMMARY: PAH patients undergoing diagnostic evaluation should be screened for a history of current or past methamphetamine use. Pharmacovigilance should be implemented to monitor patients being treated with methamphetamine for neuropsychiatric disorders (e.g., attention-deficit hyperactivity disorder). More studies will be needed to identify which susceptibility factors increase risk of PAH in methamphetamine users.
PURPOSE OF REVIEW: Methamphetamine is a highly addictive drug originally developed for the treatment of neuropsychiatric disorders. At present, the epidemic rise of illicit methamphetamine use has increased the number of patients living with medical complications. Our group has recently identified a definite association between methamphetamine use and pulmonary arterial hypertension (PAH), a life-threatening disease characterized by occlusive vasculopathy and progressive right heart failure. This review will discuss the evidence that links methamphetamine with PAH and how to approach the diagnosis and management of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) patients in clinic. RECENT FINDINGS: Compared with idiopathic (I) PAH, Meth-APAHpatients present with worse functional status, right ventricular dysfunction, and exercise tolerance. Despite therapy, the 5-year survival of Meth-APAHpatients is significantly lower compared with IPAH. Genetic studies suggest that loss of function variants in genes involved in drug detoxification can increase susceptibility for methamphetamine-related vascular injury and trigger occlusive vasculopathy. SUMMARY:PAHpatients undergoing diagnostic evaluation should be screened for a history of current or past methamphetamine use. Pharmacovigilance should be implemented to monitor patients being treated with methamphetamine for neuropsychiatric disorders (e.g., attention-deficit hyperactivity disorder). More studies will be needed to identify which susceptibility factors increase risk of PAH in methamphetamine users.
Authors: Pin-I Chen; Aiqin Cao; Kazuya Miyagawa; Nancy F Tojais; Jan K Hennigs; Caiyun G Li; Nathaly M Sweeney; Audrey S Inglis; Lingli Wang; Dan Li; Matthew Ye; Brian J Feldman; Marlene Rabinovitch Journal: JCI Insight Date: 2017-01-26
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: Stephan Schürer; Karin Klingel; Marcus Sandri; Nicolas Majunke; Christian Besler; Reinhard Kandolf; Philipp Lurz; Michael Luck; Pia Hertel; Gerhard Schuler; Axel Linke; Norman Mangner Journal: JACC Heart Fail Date: 2017-06 Impact factor: 12.035
Authors: Rajeev Malhotra; Dean Hess; Gregory D Lewis; Kenneth D Bloch; Aaron B Waxman; Marc J Semigran Journal: Pulm Circ Date: 2011-04 Impact factor: 3.017
Authors: Nicholas A Kolaitis; Roham T Zamanian; Vinicio A de Jesus Perez; David B Badesch; Raymond L Benza; Charles D Burger; Murali M Chakinala; Jean M Elwing; Jeremy Feldman; Matthew R Lammi; Stephen C Mathai; John W McConnell; Kenneth W Presberg; Jeffrey C Robinson; Jeffrey Sager; Oksana A Shlobin; Marc A Simon; Steven M Kawut; David V Glidden; Jonathan P Singer; Teresa De Marco Journal: Ann Am Thorac Soc Date: 2021-04